Kenvue Inc. (KVUE)

17.22 -0.01 (-0.09%)

As of 2025-12-02 08:33:09 EST

Kenvue Inc. is an American consumer health company. Formerly the Consumer Healthcare division of Johnson & Johnson, Kenvue owns well-known brands such as Aveeno, Band-Aid, Benadryl, Combantrin, Zyrtec, Johnson's, Listerine, Lactaid, Mylanta, Neutrogena, Trosyd, Calpol, Tylenol, and Visine. Kenvue is incorporated in Delaware and was originally headquartered in the Skillman section of Montgomery Township, New Jersey, before relocating to Summit, New Jersey.

Traded asNYSE: KVUE
ISINUS49177J1025
CIK0001944048
LEI5493008HSF8L4M2LIJ82
EIN881032011
SectorConsumer products
IndustryPerfumes, Cosmetics & Other Toilet Preparations
CEOKirk Perry
Employees22,000
Fiscal Year End1228
Address1 KENVUE WAY, SUMMIT, NJ, 07901
Phone908-874-1200
Websitehttp://kenvue.com
Stock Quotes
trading_symbolregistrant_nametimepricechangepercentage_change
KVUEKenvue Inc.2025-12-02 08:33:0917.22-0.01-0.09
This is a preview of the latest data. Subscribe to access the full data.
Company Information
trading_symbolcentral_index_keyregistrant_nameisin_numberlei_numberein_numberexchangesic_codesic_descriptionfiscal_year_endstate_of_incorporationaddress_streetaddress_cityaddress_stateaddress_zip_codeaddress_countryaddress_country_codephone_numbermailing_addressbusiness_addressformer_nameindustryfounding_datechief_executive_officernumber_of_employeeswebsitemarket_capshares_issuedshares_outstandingdescriptionupdate_time
KVUE0001944048Kenvue Inc.US49177J10255493008HSF8L4M2LIJ82881032011NYSE2844Perfumes, Cosmetics & Other Toilet Preparations1228DE1 KENVUE WAYSUMMITNJ07901UNITED STATESUS908-874-12001 KENVUE WAY, SUMMIT, NJ, 079011 KENVUE WAY, SUMMIT, NJ, 07901JNTL, Inc.Consumer products2022-02-23Kirk Perry22,000http://kenvue.com34,800,000,0001,936,118,0141,915,802,170Kenvue Inc. is an American consumer health company. Formerly the Consumer Healthcare division of Johnson & Johnson, Kenvue owns well-known brands such as Aveeno, Band-Aid, Benadryl, Combantrin, Zyrtec, Johnson's, Listerine, Lactaid, Mylanta, Neutrogena, Trosyd, Calpol, Tylenol, and Visine. Kenvue is incorporated in Delaware and was originally headquartered in the Skillman section of Montgomery Township, New Jersey, before relocating to Summit, New Jersey.2025-11-27 14:58:47
This is a preview of the latest data. Subscribe to access the full data.
KVUE Stock Price (End-of-Day)
This is a preview of the latest data. Subscribe to access the full data.
KVUE Stock Price (1-Minute)
This is a preview of the latest data. Subscribe to access the full data.
Market Cap
Fiscal YearMarket CapChange In Market CapPercentage Change In Market CapShares OutstandingChange In Shares OutstandingPercentage Change In Shares Outstanding
202434,800,000,00029,500,000,000556.60381,911,240,720-3,341,131-0.1745
20235,300,000,0005,300,000,0001001,914,581,8511,914,581,851100
This is a preview of the latest data. Subscribe to access the full data.
Executive Compensation
Executive NameExecutive PositionFiscal YearSalaryBonusStock AwardsIncentive Plan CompensationOther CompensationTotal Compensation
Carlton LawsonGroup President2024664,260750,0001,405,976516,346369,6524,495,231
Ellie Bing XieGroup President2024595,000750,0001,168,717189,4031,099,4724,311,317
Thibaut MongonChief Executive Officer20241,250,0001,500,0006,246,0041,136,875316,34313,167,969
Paul RuhChief Financial Officer2024750,0001,000,0001,405,976393,375142,2354,303,583
Meredith StevensChief Operations Officer2024595,000750,0001,168,717371,473112,6413,506,556
This is a preview of the latest data. Subscribe to access the full data.
Employee Count
Fiscal YearEmployee Count
202422,000
202322,000
This is a preview of the latest data. Subscribe to access the full data.
Income Statements
Fiscal Year20242023
Revenue15,455,000,00015,444,000,000
Cost Of Revenue6,496,000,0006,801,000,000
Gross Profit8,959,000,0008,643,000,000
Research And Development Expenses408,000,000399,000,000
General And Administrative Expenses6,329,000,0006,141,000,000
Operating Expenses——
Operating Income1,841,000,0002,512,000,000
Net Income1,030,000,0001,664,000,000
Earnings Per Share Basic0.540.9
Earnings Per Share Diluted0.540.9
Weighted Average Shares Outstanding Basic1,915,000,0001,846,135,000
Weighted Average Shares Outstanding Diluted1,923,000,0001,850,325,000
This is a preview of the latest data. Subscribe to access the full data.
Balance Sheet Statements
Fiscal Year20242023
Cash And Cash Equivalents1,070,000,0001,382,000,000
Marketable Securities Current——
Accounts Receivable2,165,000,0002,073,000,000
Inventories1,591,000,0001,851,000,000
Non Trade Receivables——
Other Assets Current205,000,000265,000,000
Total Assets Current5,525,000,0006,138,000,000
Marketable Securities Non Current——
Property Plant And Equipment1,849,000,0002,042,000,000
Other Assets Non Current726,000,000623,000,000
Total Assets Non Current1,849,000,0002,042,000,000
Total Assets25,601,000,00027,851,000,000
Accounts Payable2,254,000,0002,489,000,000
Deferred Revenue——
Short Term Debt1,552,000,000599,000,000
Other Liabilities Current1,132,000,0001,456,000,000
Total Liabilities Current5,739,000,0005,481,000,000
Long Term Debt—7,687,000,000
Other Liabilities Non Current536,000,000491,000,000
Total Liabilities Non Current10,194,000,00011,159,000,000
Total Liabilities15,933,000,00016,640,000,000
Common Stock19,000,00019,000,000
Retained Earnings-93,000,000429,000,000
Accumulated Other Comprehensive Income-6,146,000,000-5,377,000,000
Total Shareholders Equity9,668,000,00011,211,000,000
This is a preview of the latest data. Subscribe to access the full data.
Cash Flow Statements
Fiscal Year20242023
Depreciation And Amortization622,000,000322,000,000
Share Based Compensation Expense254,000,000188,000,000
Other Non Cash Income Expense-69,000,000-6,000,000
Change In Accounts Receivable218,000,000-44,000,000
Change In Inventories-182,000,000-349,000,000
Change In Non Trade Receivables——
Change In Other Assets17,000,000429,000,000
Change In Accounts Payable-536,000,000390,000,000
Change In Other Liabilities52,000,000-212,000,000
Cash From Operating Activities1,769,000,0003,168,000,000
Purchases Of Marketable Securities——
Sales Of Marketable Securities——
Acquisition Of Property Plant And Equipment434,000,000469,000,000
Acquisition Of Business——
Other Investing Activities-15,000,00040,000,000
Cash From Investing Activities-425,000,000-488,000,000
Tax Withholding For Share Based Compensation——
Payments Of Dividends1,552,000,000766,000,000
Issuance Of Common Stock——
Repurchase Of Common Stock235,000,000—
Issuance Of Long Term Debt——
Repayment Of Long Term Debt——
Other Financing Activities63,000,000-186,000,000
Cash From Financing Activities-1,565,000,000-2,527,000,000
Change In Cash-312,000,000151,000,000
Cash At End Of Period1,070,000,0001,382,000,000
Income Taxes Paid810,000,000699,000,000
Interest Paid439,000,000224,000,000
This is a preview of the latest data. Subscribe to access the full data.
Key Metrics
Fiscal Year2024
Earnings Per Share0.54
Price To Earnings Ratio39.2222
Earnings Growth Rate-40
Price Earnings To Growth Ratio-0.9806
Book Value Per Share5.0486
Price To Book Ratio4.1953
Ebitda2,893,000,000
Enterprise Value—
Dividend Yield0.0383
Dividend Payout Ratio1.5068
Debt To Equity Ratio—
Capital Expenditures429,000,000
Free Cash Flow1,340,000,000
Return On Equity0.1065
One Year Beta0.2721
Three Year Beta0.436
Five Year Beta0.436
This is a preview of the latest data. Subscribe to access the full data.
Insider Transactions
Insider NameRelationship To IssuerTransaction DateAmount Of SecuritiesAcquired Or DisposedSecurities Owned Following Transaction
Stevens MeredithChief Operations Officer2025-11-18494A64,935
Stevens MeredithChief Operations Officer2025-11-18494D64,441
Stevens MeredithChief Operations Officer2025-11-18166A64,607
Stevens MeredithChief Operations Officer2025-11-18494D12,074
Stevens MeredithChief Operations Officer2025-11-18166D15,485
This is a preview of the latest data. Subscribe to access the full data.
Senate Trading
Name Of Reporting PersonType Of Reporting PersonReport DateTransaction TypeTransaction DateOwner TypeAmount
Sheldon WhitehouseSenator2025-09-03Sale (Full)2025-08-28Spouse$1,001 - $15,000
Sheldon WhitehouseSenator2024-12-05Sale (Full)2024-11-18Self$1,001 - $15,000
Sheldon WhitehouseSenator2023-10-17Purchase2023-09-20Self$1,001 - $15,000
This is a preview of the latest data. Subscribe to access the full data.
House Trading
Name Of Reporting PersonReport DateStateTransaction TypeTransaction DateOwner TypeAmount
Lisa McClain2025-11-21MI09Sale2025-10-30Spouse$1,001 - $15,000
Lisa McClain2025-11-21MI09Purchase2025-10-30Spouse$1,001 - $15,000
Lisa McClain2025-11-21MI09Sale2025-10-31Spouse$1,001 - $15,000
Lisa McClain2025-10-22MI09Purchase2025-09-25Spouse$1,001 - $15,000
Valerie Hoyle2025-10-10OR04Sale2025-09-23Spouse$1,001 - $15,000
This is a preview of the latest data. Subscribe to access the full data.
Institutional Holdings
Investor NamePeriod Of ReportMarket ValueAmount Of SecuritiesPrice Per Security
JPMORGAN CHASE & CO2025-09-30331,339,99320,414,85416.2303
Vermillion & White Wealth Management Group, LLC2025-09-3010,55065016.2308
CHELSEA COUNSEL CO2025-09-30330,03820,33516.23
BURKETT FINANCIAL SERVICES, LLC2025-09-3027,8051,71316.2318
CIBC Private Wealth Group LLC2025-09-30103,6726,38816.2292
This is a preview of the latest data. Subscribe to access the full data.
Mutual Fund Holdings
Registrant NamePeriod Of ReportFund NameFund SymbolAmount Of UnitsValue In UsdPercentage Value Compared To Assets
Voya INVESTORS TRUST2025-09-30Class IINGIX87,6051,421,829.150.0533
Voya INVESTORS TRUST2025-09-30Class R6VLCRX588,5279,551,793.211.8536
Voya INVESTORS TRUST2025-09-30Class S2IPETX588,5279,551,793.211.8536
Voya INVESTORS TRUST2025-09-30Class SIPESX588,5279,551,793.211.8536
Voya INVESTORS TRUST2025-09-30Class IIPEIX588,5279,551,793.211.8536
This is a preview of the latest data. Subscribe to access the full data.